Provigil, Nuvigil, Modafinil Antitrust Settlements

Settlement Structure: Claims Made

Active: Closed

Closed Settlement Statement:
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.

Case Summary:

An antitrust class action and an antitrust case brought by the California Attorney General (CAAG) on the same topic are being settled at the same time. The suits claim that drug companies conspired to keep prices of the original drug Provigil high by delaying the introduction of generics and (in the CAAG suit) of Nuvigil.

The class action named as defendants Cephalon, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc. and Mylan, Inc., Sun Pharmaceuticals Industries, Ltd. (successor-in-interest to Ranbaxy Laboratories, Ltd.) and Ranbaxy Pharmaceuticals, Inc.

The CAAG case named as defendants Teva Pharmaceutical Industries Ltd. and its wholly-owned subsidiaries Cephalon, Inc., Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc.

Docket Number:

06-CV-1833 and 19-CV-03281

Company: Teva Pharmaceutical Industries

Filing Deadline: January 15, 2020

Class Period: June 24, 2006 to August 8, 2019

Objection Deadline: January 15, 2020

Exclusion Deadline: December 6, 2019

Final Approval Hearing: February 26, 2020

Proof of Purchase:

See the respective notices and claim forms for details.

Eligibility:

You may be eligible in the class action if you were a consumer or third-party payor (TPP) who paid for Provigil or Modafinil which were meant for consumption by yourself, your family, or your members, plan participants, beneficiaries or insured, in the states listed below, between June 24, 2006 and August 8, 2019:

Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee, Utah, Vermont, West Virginia and Wisconsin.

You may be eligible in the CAAG case if you bought or paid for Provigil, Nuvigil, or Modafinil as a caregiver or for your personal consumption in any state from June 24, 2006 through December 31, 2010 and you were a California resident at the time of each purchase.

For exclusions or more details, see the website and respective notices.

Typical Settlement Amount:

Amounts depend on amounts purchased by each claimant and other factors. See the website and respective notices for details.

Total Settlement Amount: Class action: $65,877,600; CAAG: $69,000,000

Class Representative Proposed Incentive Fee:

Class action: $15,000-$50,000

Law Firms:
California Attorney General
Criden & Love
Kessler Topaz Meltzer Check LLP
Spector Roseman & Kodroff PC

Claim Form: Provigil, Nuvigil, Modafinil Antitrust Settlement Claim Forms

Case Name: Vista Healthplan, Inc. et al. v. Cephalon, Inc. et al. and State of California v. Teva Pharm. Indus. Ltd.

Settlement Website: Provigil, Nuvigil, Modafinil Antitrust Settlement Website

Claims Administrator:
AB Data, Ltd.

Claims Administrator Contact Information:

Provigil Settlement
c/o A.B. Data, Ltd.
P.O. Box 170300
Milwaukee, WI 53217
1-877-241-7503
info@ProvigilSettlement.com

Tags: Antitrust, Drugs and Generics, Inflated Drug Prices